WO2013190165A1 - Compuestos con funcionalidad magnética, implantes o geles derivados de ellos, y el uso de ambos para determinar la actividad enzimática de una enzima - Google Patents
Compuestos con funcionalidad magnética, implantes o geles derivados de ellos, y el uso de ambos para determinar la actividad enzimática de una enzima Download PDFInfo
- Publication number
- WO2013190165A1 WO2013190165A1 PCT/ES2013/070407 ES2013070407W WO2013190165A1 WO 2013190165 A1 WO2013190165 A1 WO 2013190165A1 ES 2013070407 W ES2013070407 W ES 2013070407W WO 2013190165 A1 WO2013190165 A1 WO 2013190165A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnetic
- compound
- substrate
- particles
- implant
- Prior art date
Links
- 230000005291 magnetic effect Effects 0.000 title claims abstract description 289
- 150000001875 compounds Chemical class 0.000 title claims abstract description 168
- 239000007943 implant Substances 0.000 title claims abstract description 108
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 104
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 104
- 239000000499 gel Substances 0.000 title claims description 81
- 230000000694 effects Effects 0.000 title abstract description 52
- 239000006249 magnetic particle Substances 0.000 claims abstract description 181
- 239000000758 substrate Substances 0.000 claims abstract description 151
- 102000008186 Collagen Human genes 0.000 claims abstract description 95
- 108010035532 Collagen Proteins 0.000 claims abstract description 95
- 229920001436 collagen Polymers 0.000 claims abstract description 95
- 239000002245 particle Substances 0.000 claims abstract description 76
- 238000012986 modification Methods 0.000 claims abstract description 66
- 230000004048 modification Effects 0.000 claims abstract description 64
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 54
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 54
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 53
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 44
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 41
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 41
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 41
- 238000000576 coating method Methods 0.000 claims abstract description 39
- 239000011248 coating agent Substances 0.000 claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 claims abstract description 29
- 229960005188 collagen Drugs 0.000 claims description 87
- 238000000034 method Methods 0.000 claims description 67
- 230000008929 regeneration Effects 0.000 claims description 59
- 238000011069 regeneration method Methods 0.000 claims description 59
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 43
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 42
- 230000002255 enzymatic effect Effects 0.000 claims description 41
- 210000002808 connective tissue Anatomy 0.000 claims description 27
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 claims description 27
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical group CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 230000002776 aggregation Effects 0.000 claims description 23
- 238000004220 aggregation Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 238000006911 enzymatic reaction Methods 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 206010016654 Fibrosis Diseases 0.000 claims description 14
- 230000005298 paramagnetic effect Effects 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 11
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 11
- 230000010354 integration Effects 0.000 claims description 11
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 11
- 102000003886 Glycoproteins Human genes 0.000 claims description 10
- 108090000288 Glycoproteins Proteins 0.000 claims description 10
- 238000005481 NMR spectroscopy Methods 0.000 claims description 10
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 9
- 239000002872 contrast media Substances 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 102000016942 Elastin Human genes 0.000 claims description 8
- 108010014258 Elastin Proteins 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 230000007882 cirrhosis Effects 0.000 claims description 8
- 229920002549 elastin Polymers 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000007547 Laminin Human genes 0.000 claims description 7
- 108010085895 Laminin Proteins 0.000 claims description 7
- 108060002895 fibrillin Proteins 0.000 claims description 7
- 102000013370 fibrillin Human genes 0.000 claims description 7
- 230000004761 fibrosis Effects 0.000 claims description 7
- 238000005404 magnetometry Methods 0.000 claims description 7
- 102000035118 modified proteins Human genes 0.000 claims description 7
- 108091005573 modified proteins Proteins 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 102000004264 Osteopontin Human genes 0.000 claims description 6
- 108010081689 Osteopontin Proteins 0.000 claims description 6
- 230000005350 ferromagnetic resonance Effects 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 238000009792 diffusion process Methods 0.000 claims description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 208000004362 Penile Induration Diseases 0.000 claims description 4
- 208000020758 Peyronie disease Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000002983 circular dichroism Methods 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 230000003100 immobilizing effect Effects 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 238000004611 spectroscopical analysis Methods 0.000 claims description 4
- 230000007863 steatosis Effects 0.000 claims description 4
- 208000001708 Dupuytren contracture Diseases 0.000 claims description 3
- 230000005374 Kerr effect Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 230000005408 paramagnetism Effects 0.000 claims description 3
- 230000006798 recombination Effects 0.000 claims description 3
- 230000017423 tissue regeneration Effects 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 238000004630 atomic force microscopy Methods 0.000 claims description 2
- 230000003848 cartilage regeneration Effects 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 102000004067 Osteocalcin Human genes 0.000 claims 3
- 108090000573 Osteocalcin Proteins 0.000 claims 3
- 102000009890 Osteonectin Human genes 0.000 claims 3
- 108010077077 Osteonectin Proteins 0.000 claims 3
- 238000000149 argon plasma sintering Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 abstract description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 11
- 230000001172 regenerating effect Effects 0.000 abstract 3
- 229940088598 enzyme Drugs 0.000 description 93
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 239000000463 material Substances 0.000 description 32
- 239000002069 magnetite nanoparticle Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 230000005415 magnetization Effects 0.000 description 21
- 230000008569 process Effects 0.000 description 21
- 239000000725 suspension Substances 0.000 description 20
- 102000029816 Collagenase Human genes 0.000 description 19
- 108060005980 Collagenase Proteins 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 17
- 239000013078 crystal Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000002609 medium Substances 0.000 description 16
- -1 osteacalcin Polymers 0.000 description 16
- 230000006870 function Effects 0.000 description 14
- 239000002105 nanoparticle Substances 0.000 description 14
- 229960002424 collagenase Drugs 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 229920000936 Agarose Polymers 0.000 description 12
- 210000000845 cartilage Anatomy 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 229920000656 polylysine Polymers 0.000 description 12
- 238000009826 distribution Methods 0.000 description 11
- 230000005294 ferromagnetic effect Effects 0.000 description 11
- 239000002122 magnetic nanoparticle Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 108010039918 Polylysine Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000003366 colagenolytic effect Effects 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- 102000012422 Collagen Type I Human genes 0.000 description 8
- 108010022452 Collagen Type I Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000017 hydrogel Substances 0.000 description 8
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000003302 ferromagnetic material Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 102000005741 Metalloproteases Human genes 0.000 description 6
- 108010006035 Metalloproteases Proteins 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229910000859 α-Fe Inorganic materials 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- 229920001661 Chitosan Polymers 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 5
- 102000005262 Sulfatase Human genes 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000009739 binding Methods 0.000 description 5
- 239000000560 biocompatible material Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 230000005381 magnetic domain Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 108060007951 sulfatase Proteins 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 4
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 238000004873 anchoring Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000000696 magnetic material Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 102000004266 Collagen Type IV Human genes 0.000 description 3
- 108010042086 Collagen Type IV Proteins 0.000 description 3
- 108010026132 Gelatinases Proteins 0.000 description 3
- 102000013382 Gelatinases Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 108010077465 Tropocollagen Proteins 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002889 diamagnetic material Substances 0.000 description 3
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 150000002669 lysines Chemical class 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000005401 siloxanyl group Chemical group 0.000 description 3
- 125000003011 styrenyl group Chemical class [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 102100027995 Collagenase 3 Human genes 0.000 description 2
- 108050005238 Collagenase 3 Proteins 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000005292 diamagnetic effect Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000005293 ferrimagnetic effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 102000013373 fibrillar collagen Human genes 0.000 description 2
- 108060002894 fibrillar collagen Proteins 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000001865 kupffer cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000005389 magnetism Effects 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002907 paramagnetic material Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DGPVNNMFVYYVDF-UHFFFAOYSA-N 1-prop-2-enoylpyrrolidin-2-one Chemical compound C=CC(=O)N1CCCC1=O DGPVNNMFVYYVDF-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- HXLAEGYMDGUSBD-UHFFFAOYSA-N 3-[diethoxy(methyl)silyl]propan-1-amine Chemical compound CCO[Si](C)(OCC)CCCN HXLAEGYMDGUSBD-UHFFFAOYSA-N 0.000 description 1
- GLISOBUNKGBQCL-UHFFFAOYSA-N 3-[ethoxy(dimethyl)silyl]propan-1-amine Chemical compound CCO[Si](C)(C)CCCN GLISOBUNKGBQCL-UHFFFAOYSA-N 0.000 description 1
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000004427 Collagen Type IX Human genes 0.000 description 1
- 108010042106 Collagen Type IX Proteins 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 102000004510 Collagen Type VII Human genes 0.000 description 1
- 108010017377 Collagen Type VII Proteins 0.000 description 1
- 102000001191 Collagen Type VIII Human genes 0.000 description 1
- 108010069526 Collagen Type VIII Proteins 0.000 description 1
- 102000030746 Collagen Type X Human genes 0.000 description 1
- 108010022510 Collagen Type X Proteins 0.000 description 1
- 102000009736 Collagen Type XI Human genes 0.000 description 1
- 108010034789 Collagen Type XI Proteins 0.000 description 1
- 102000014870 Collagen Type XII Human genes 0.000 description 1
- 108010039001 Collagen Type XII Proteins 0.000 description 1
- 102000009089 Collagen Type XIII Human genes 0.000 description 1
- 108010073180 Collagen Type XIII Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 241000207439 Myra Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229910002808 Si–O–Si Inorganic materials 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical group OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NJSVDVPGINTNGX-UHFFFAOYSA-N [dimethoxy(propyl)silyl]oxymethanamine Chemical compound CCC[Si](OC)(OC)OCN NJSVDVPGINTNGX-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-SXUWKVJYSA-N alpha-L-galactose Chemical compound OC[C@@H]1O[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-SXUWKVJYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000005290 antiferromagnetic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical group CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940107200 chondroitin sulfates Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000002902 ferrimagnetic material Substances 0.000 description 1
- 230000005308 ferrimagnetism Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 210000003458 notochord Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- CAPBXYLOGXJCFU-UHFFFAOYSA-N oxiran-2-ylmethoxysilane Chemical class [SiH3]OCC1CO1 CAPBXYLOGXJCFU-UHFFFAOYSA-N 0.000 description 1
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 125000005702 oxyalkylene group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000141 poly(maleic anhydride) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 108010062573 polycationic ferritin Proteins 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009774 resonance method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 238000002444 silanisation Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 1
- 229960005346 succimer Drugs 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- TXDNPSYEJHXKMK-UHFFFAOYSA-N sulfanylsilane Chemical class S[SiH3] TXDNPSYEJHXKMK-UHFFFAOYSA-N 0.000 description 1
- 238000005308 sum rule Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001604 vasa vasorum Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000002460 vibrational spectroscopy Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
Definitions
- the present invention generally relates to an implant or a gel comprising at least one compound with magnetic functionality. These implants or gels can be used to determine the enzymatic activity associated with cell matrix regeneration by measuring the variation in the magnetic properties of at least one of the compounds with magnetic functionality, in the magnetic properties of one or more of its degradation products, or both.
- the present invention also relates to new compounds with magnetic functionality comprising a substrate of at least one enzyme, preferably collagen, chondroitin sulfate or hyaluronic acid, and a plurality of magnetic particles without coating or surface modification, or functionalized with groups carboxylic.
- Enzymes are proteins that catalyze chemical reactions. In enzymatic reactions the molecules on which an enzyme acts are called substrates and are converted by enzymes into different molecules called metabolites. Enzymes are generally very specific regarding the reactions and substrates they catalyze.
- Magnetic particles bound to a macromolecule of biological origin can produce a magnetic signature different from that of the macromolecule itself of biological origin. This magnetic signature is a function of the composition, size and shape of the particles.
- the magnetization of a certain material is defined as its average magnetic moment per unit volume and is determined by the internal structure and composition of said material.
- Examples of magnetic particles include paramagnetic, superparamagnetic and ferromagnetic particles; which are commonly used as contrast agents in the form of individual particles, microencapsulated in matrices or bound to other molecules. These magnetic contrast agents are designed to maintain their constant magnetic properties during measurements and produce image effects according to their concentration and distribution in the different tissues and compartments of the body. Certain factors in the distribution of magnetic particles such as aggregation or surface coatings can affect the contrast effects they produce.
- compound with magnetic functionality is understood as the one with the capacity to undergo conformational or structural changes that give rise to a measurable variation of its magnetic properties, in the magnetic properties of one or more of its degradation products , or both.
- US patent application 2011/0182815 A1 (Daich, J.) describes diagnostic methods using modified substrates to have magnetic functionality. Said substrates are obtained from the combination thereof with magnetic particles so that being these substrates with magnetic functionality digested by the enzymes of interest a measurable change in the distribution of the magnetic particles occurs.
- US patent application 2011/0182815 A1 only mentions pharmaceutical formulations that include intravenous and encapsulation methods as forms of delivery of said modified substrates to have magnetic functionality that are not efficient to reach certain types of connective tissue as they may be different.
- the compounds with magnetic functionality and the methods for obtaining them described in the patent application US 201 1/0182815 A1 are based on the use of magnetic particles with surface modifications, which facilitate the anchoring of said magnetic particles to the substrates of interest.
- Said surface modifications are made with diamagnetic materials, resulting in a decrease in the intensity and scope of the magnetic field that these particles with surface modifications generate in their environment. Therefore, when these surface modifications are incorporated into the magnetic particles, the interaction between the magnetic moments of the different particles can be reduced, these phenomena being disadvantageous for the type of measurements used in detection methods such as nuclear magnetic resonance proposed in the aforementioned American patent application.
- Patent application WO 201 1/075476 A1 (Bennett K, 2011) describes methods for evaluating the molecular structure of biocompatible hydrogels using nuclear magnetic resonance (MRI) techniques. To do this, it describes gels comprising a biocompatible hydrogel and a magnetic contrast agent. This gel can be implanted in vivo so that the disintegration of the magnetic particles comprised in the agent Contrast, as a result of the interaction of the interaction of the hydrogel with the cells of the extracellular matrix, or the enzymatic action, can be determined by MRI. In particular, this document discloses the use of cationized ferritin as a contrast agent. This compound binds to the hydrogel through the anionic groups present in the structure of said hydrogel.
- MRI nuclear magnetic resonance
- the term "aggregation" is used on a recurring basis to define the immobilization or fixation of particles in the gel which does not imply the formation of aggregates of particles as such. Additionally, the incorporation of an enzymatic precursor to the gel to amplify the degradation rate of the gel is described. However, since this degradation is the result of a cascade reaction of the activation of a preimplanted precursor of an enzyme and not of the target enzyme, this method loses precision in the intensity and duration of the enzymatic activity under study.
- the present invention relates to an implant or a gel comprising at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles.
- the gel comprising at least one compound with magnetic functionality as described in this patent application is suitable for in vitro analysis and can additionally include the same biocompatible materials as an implant.
- Such gels are commonly used to simulate the extracellular matrix environment and have varied applications in research and diagnosis.
- the present invention relates to a compound with magnetic functionality comprising a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles for manufacturing an implant or a gel for monitoring enzymatic activity. involved in the regeneration of the extracellular matrix in a human being or other living being.
- the present invention also relates to the use of said compound with magnetic functionality to manufacture an implant or a gel to monitor an enzymatic activity involved in the regeneration process of the extracellular matrix in a human being or other living being.
- the compound with magnetic functionality included therein can react with at least one enzyme involved in the regeneration of the extracellular matrix, resulting in a measurable variation in its magnetic properties, in the magnetic properties. of one or more of its degradation products, or both.
- the present invention provides an implant that allows the regeneration of the extracellular matrix in said implant to be monitored without the need for biopsies.
- the present invention also relates to a compound with magnetic functionality comprising a substrate of at least one enzyme and a plurality of magnetic particles, said compound characterized in that:
- the magnetic particles have no coating or surface modification, or
- the magnetic particles are functionalized with carboxylic groups.
- the compound with magnetic functionality of the present invention can react with at least one enzyme resulting in a measurable variation in its magnetic functionality.
- the compound with magnetic functionality of the present invention can be used for the detection of an enzymatic activity, in particular that involved in the regeneration of the extracellular matrix.
- step b) immobilize a plurality of magnetic particles that do not exhibit any coating or surface modification in the modified compound obtained in step a).
- the process of obtaining a compound with magnetic functionality of this invention allows the enzyme substrate to be bound to magnetic particles which are almost entirely magnetic core itself.
- the magnetic particles are superparamagnetic particles.
- the substrate may be selected from the group consisting of protein, modified protein, polypeptide, modified polypeptide, glycoprotein, glycosaminoglycan and mixtures thereof, it being more preferable that said substrate is selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid.
- the present invention also relates to a compound with magnetic functionality comprising a substrate of at least one enzyme and a plurality of magnetic particles that do not have any coating or surface modification, wherein said compound with magnetic functionality is obtained by the procedure described in this patent application.
- the magnetic particles are magnetite nanoparticles
- the substrate can be selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid.
- the present invention also relates to a product comprising at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles, wherein
- the magnetic particles have no coating or surface modification, or
- the magnetic particles are functionalized with carboxylic groups as described in this patent application, wherein said product is selected from the group consisting of an implant, a gel, a pharmaceutical composition and a contrast agent.
- the present invention relates to a product that is selected from the group consisting of an implant and a gel, and this comprises at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme involved in the process. of cell regeneration and a plurality of magnetic particles, where i) the magnetic particles have no coating or surface modification, or ii) the magnetic particles are functionalized with carboxylic groups as described in this patent application.
- the substrate is selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid, and the magnetic particles are magnetite nanoparticles without coating or surface modification.
- the present invention also relates to the use of the compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles, where i) the magnetic particles do not exhibit any coating or surface modification, or ii)
- the magnetic particles are functionalized with carboxylic groups as described in this patent application, to manufacture a product as described in this patent application to determine the enzymatic activity of one or more enzymes.
- the present invention also relates to the use of the compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles, where i) the magnetic particles do not exhibit any coating or surface modification, or ii) the magnetic particles are functionalized with carboxylic groups as described in this patent application, to manufacture the implant or the gel as described in this patent application to monitor an enzymatic activity involved in the regeneration of the extracellular matrix in a human being or another living being.
- the present invention makes use, among other principles, of the fact that the properties of magnetic materials are derived from the distribution and shape of their components. If it is possible to alter any of these two characteristics through enzymatic activity, it is possible to detect it depending on the measurement of the magnetic properties. One way to do the latter is to cause particle aggregation as a result of enzymatic activity. To understand the effect of the aggregation of magnetic particles, a general description of the properties of the different types of magnetic materials that can compose them is given first.
- Ferromagnetic materials in general contain transition metals such as iron (Fe), magnesium (Mg), manganese (Mn), cobalt (Co), nickel (Ni), zinc (Zn) and copper (Cu). Ferromagnetic materials are also characterized by being formed by groups of about 10 17 to 10 21 atoms called magnetic domains, all of them having their magnetic moments (or spin populations) that point in the same direction. The magnetic moments of the domains are randomly oriented in non-magnetized materials, and point in preferred directions in magnetized materials. The ability of ferromagnetic materials to remain magnetized when an external magnetic field is removed is a distinctive factor compared to paramagnetic, superparamagnetic and diamagnetic materials that lose their preferred magnetization orientation in similar circumstances.
- transition metals such as iron (Fe), magnesium (Mg), manganese (Mn), cobalt (Co), nickel (Ni), zinc (Zn) and copper (Cu).
- Ferromagnetic materials are also characterized by being formed by groups of about 10 17 to 10 21 atoms
- Certain paramagnetic materials may have permanent and stable magnetization after removing the magnetic field if they are below the call.
- Curie temperature transition temperature below which the spins are stably aligned for or against the magnetic field. These materials are called antiferomagnetic and have a resulting magnetization because the two orientations of the spins are not canceled.
- Above the Curie temperature since the interaction of the spins is weak, when removing the external magnetic field the thermal agitation is sufficient for the spins to acquire a random orientation thus eliminating permanent magnetization.
- All magnetite-based iron particles have ferrimagnetic or ferromagnetic properties at physiological temperatures (the transition temperature of iron particles is close to 850 Kelvin).
- Superparamagnetic materials may consist of individual domains of bulk materials that possess ferromagnetic properties. Its magnetic susceptibility, the degree of magnetization of a material, in response to a magnetic field, is between that of ferromagnetic and paramagnetic materials. Superparamagnetic materials behave like ferromagnetic materials under the effects of external magnetic fields, but have paramagnetic characteristics in the absence of an external magnetic field. These superparamagnetic materials are generally formed by nanometric crystalline particles, and on a macroscopic scale they have ferromagnetic or nanocomposite magnet properties.
- the concept of anisotropy is important to understand superparamagnetism.
- the spins of a large number of paramagnetic ions arranged in an orderly manner interact so that when placed in an external field, the resulting magnetization is oriented in all directions, that is, it is isotropic.
- the coupling of the spins is aligned in some direction in relation to an external field then the magnetization is said to be anisotropic.
- the result would be six orientations, each with a different energy value. The minimum energies are given when the orientation is parallel to the external field, and maximum when the orientation is antiparallel.
- Temperature has a destabilizing effect on the magnetism of superparamagnetic materials. Thermal energy prevents alignment of magnetic moments present in superparamagnetic particles. After the removal of an applied magnetic field, the magnetic moments of the superparamagnetic materials still exist but the rapid temperature-induced movement misaligns them. At the temperatures of biological systems and in the applied magnetic fields of magnetic resonance imaging (RMI), superparamagnetic materials are less magnetizable than their ferromagnetic counterparts.
- RMI magnetic resonance imaging
- Certain magnetic properties arise from the cooperative behavior of domains at macroscopic scales and are not intrinsic to the molecules or ions that make up the material. These properties are a consequence of the interactions between the molecules or ions and, therefore, the methods to predict, control and modulate the solid state structure are relevant to the understanding and manipulation of such behavior.
- Some nanomaterials such as colloidal suspension magnetite nanoparticles, exhibit certain properties different from those they possess in solid state at macroscopic scales, either in bulk or as individual particles. For materials formed by large crystals, diameters greater than 15 nm, the spins are aligned and subdivided into small magnetic domains called Weiss domains.
- Néel's relaxation T n
- T is the constant temperature of the medium and ⁇ 0 is a constant.
- T is the constant temperature of the medium and ⁇ 0 is a constant.
- the relaxation time of Néel is very long and the magnetic moments can be considered as blocked to the easy anisotropic axis.
- the transmissions are fast in the order of nanoseconds.
- Brownian time or average system rotation is equal to:
- ⁇ is the radius of the particle and ⁇ the viscosity of the liquid.
- B 0 is the external magnetic field
- ⁇ is the total magnetic moment of the crystal
- M sa t defines the closing field of the magnetization or saturation along the low energy axis.
- the superparamagnetic particles have much greater magnetic moments than the individual moments associated with the ions that form the crystals due to the fact that, in the absence of an external field, the average magnetic moment of the particles is zero due to the average relaxation level. the crystals and the rotation of the particles.
- the present invention is based on the fact that the magnetic behavior of magnetic nanoparticles depends on the distance between them and that this difference is experimentally measurable.
- the distance between said magnetic nanoparticles immobilized in a matrix or in a macromolecule depends on the integrity of said support. If this integrity is altered by the effect of a hydrolytic enzyme, for example, and if by this effect the magnetic particles will be added, a different magnetic signal will be produced from that of the particles present in an intact matrix or molecule.
- the present invention relates to an implant or a gel comprising at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles, with the condition that when the implant or gel comprises more than one compound with magnetic functionality, they are located in different regions.
- the implant or gel comprises more than one compound with magnetic functionality as described in this patent application, these are arranged in separate areas of the implant or gel.
- the use of an implant or gel comprising more than one compound with magnetic functionality, each comprising a different substrate can allow simultaneous monitoring of different enzymes.
- plural of magnetic particles means more than one non-diamagnetic particle;
- particle being also understood as a combination of molecules or ions, preferably arranged in the form of a crystal, with a micrometric or smaller size, preferably with a size smaller than 100 nm in diameter.
- compound with magnetic functionality is understood as that compound with the ability to produce conformational or structural changes that give rise to a measurable variation of its magnetic properties, in the magnetic properties of one or more of its degradation products, or both. It is necessary that compounds with magnetic functionality preserve their functional properties during gel preparation or exposure to physiological conditions.
- the implant or gel of the present invention comprises a compound with magnetic functionality which in turn comprises a plurality of magnetic particles bonded through covalent bonds to the substrate of at least one enzyme involved in the regeneration of the extracellular matrix.
- the present invention relates to the implant or gel comprising a compound with magnetic functionality which in turn comprises a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles as it is described in this patent application.
- the present invention relates to the implant or gel comprising at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles such as described in this patent application, where the magnetic particles are superparamagnetic particles.
- the superparamagnetic particles may be ferrite nanoparticles, such as magnetite, maghemite, cobalt, silver or magnesium ferrites.
- These preferred magnetic particles allow covalent bonds with the substrate. Additionally, they can be added at physiological pH.
- the superparamagnetic particles are magnetite nanoparticles, it being especially preferable that the magnetite nanoparticles have a diameter less than 15 nm.
- the present invention relates to the implant or gel comprising at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles such as described in this patent application, where the substrate can be selected from the group consisting of protein, modified protein, polypeptide, modified polypeptide, glycoprotein, glycosaminoglycan and a combination thereof.
- said substrate reacts with at least one enzyme that is a metal dependent enzyme.
- this enzyme is selected from the group consisting of a protease, an oxidase and a sulfatase. Even more preferably, this enzyme is selected from the group consisting of hyaluronidase and a metalloprotease.
- the substrate comprised in the compound with magnetic functionality described in this patent application reacts with at least one enzyme that is a matrix metalloprotease (MMP), it being especially preferable that this enzyme is selected from the group consisting of a collagenase and a gelatinase.
- MMP matrix metalloprotease
- the present invention relates to the implant or gel comprising at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of particles.
- the substrate can be selected from the group consisting of collagen, fibrillin, elastin, laminin, osteacalcin, chondroitin sulfate, hyaluronic acid, osteanectin, osteopontin, gelatin and a combination thereof.
- the substrate can be selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid.
- the implant or gel comprises a compound with magnetic functionality
- the magnetic particles are superparamagnetic particles, preferably magnetite nanoparticles
- the substrate can be selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid. Even more preferably, magnetite nanoparticles are linked through covalent bonds to the substrate.
- the present invention also relates to a compound with magnetic functionality comprising a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles, for manufacturing an implant or a gel for monitoring an enzymatic activity involved in the regeneration of the extracellular matrix.
- the manufactured product When the manufactured product is an implant, it can be used to monitor an enzymatic activity involved in the regeneration of the extracellular matrix in a human being or other living being. On the other hand, when the manufactured product is a gel, it can be used to monitor an enzymatic activity involved in the regeneration of the extracellular matrix in vitro.
- the magnetic particles may be superparamagnetic particles and, more preferably, magnetite nanoparticles.
- the compound with magnetic functionality used to make the implant or gel as described in turn comprises a plurality of magnetic particles bonded through covalent bonds to the substrate of at least one enzyme involved in the regeneration of the extracellular matrix.
- the substrate comprised in the compound with magnetic functionality to manufacture the implant or gel as described in the previous paragraph can be selected from the group consisting of protein, modified protein, polypeptide, modified polypeptide, glycoprotein, glycosaminoglycan and a combination of these.
- the present invention relates to the compound with magnetic functionality comprising a substrate of at least one enzyme in the regeneration of the extracellular matrix and a plurality of magnetic particles as described in this patent application, where
- the substrate can be selected from the group consisting of collagen, fibrillin, elastin, laminin, osteacalcin, chondroitin sulfate, hyaluronic acid, osteanectin, osteopontin, gelatin and a combination thereof.
- the substrate can be selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid.
- the magnetic particles are superparamagnetic particles, preferably magnetite nanoparticles
- the substrate can be selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid. Even more preferably, magnetite nanoparticles are linked through covalent bonds to the substrate.
- Collagen has a complex structure. Its precursor protein (monomer) is called tropocollagen and measures about 300 nanometers in length and 1.4 nm in diameter.
- the tropocollagen is made up of three polypeptide chains called alpha chains, which in turn intersect to form a triple helical structure.
- Each ⁇ chain is a polypeptide formed by the repetition of triplets that contain glycine amino acids as a whole and is very rich in proline and hydroxyproline. Hydroxyproline represents between 10 and 12% of the total composition of the collagen residues, said percentage depending on the type of collagen.
- Each chain has a molecular weight of around 100,000 Da.
- Type I collagen It is found abundantly in the dermis, bone, tendon and cornea. It occurs in striated fibrils of 20 to 100 nm in diameter, grouping together to form larger collagen fibers. Its major subunits are constituted by alpha chains of two types, which differ slightly in their amino acid composition and sequence. One of which is designated as alfal chain and the other, alpha2 chain. It is synthesized by fibroblasts, chondroblasts and osteoblasts. Its main function is that of stretch resistance.
- Type II collagen It is found mostly in cartilage, but it also occurs in the embryonic cornea and in the notochord, in the nucleus pulposus and in the vitreous humor of the eye.
- cartilage In cartilage it forms fine fibrils of 10 to 20 nanometers, but in other microenvironments it can form larger fibrils, morphologically indistinguishable from type I collagen. They consist of three alpha2 chains of a single type. It is synthesized by chondroblast. Its main function is resistance to intermittent pressure.
- Type III collagen Abundant in loose connective tissue, blood vessel walls, skin dermis and stroma of several glands. It seems an important constituent of 50 nanometer fibers that have traditionally been called reticular fibers. It consists of a unique class of alpha3 string. It is synthesized by smooth muscle cells, fibroblasts, glia. Its function is to support the expandable organs.
- Type IV collagen It is the collagen that forms the basal lamina that underlies the epithelia. It is a collagen that does not polymerize in fibrils, but forms a filter of randomly oriented molecules, associated with proteoglycans and with the structural proteins laminin and fibronectin. It is synthesized by epithelial and endothelial cells. Its main function is the support and filtration.
- Type V collagen Present in most interstitial tissue. It is associated with type I.
- Type VI collagen Present in most interstitial tissue. It serves as an anchor for cells in their environment. It is associated with type I.
- Type VII collagen It is found in the basal lamina.
- Type VIII collagen Present in some endothelial cells.
- Type IX collagen It is found in mature articular cartilage. Interact with type II.
- Type X collagen Present in hypertrophic and mineralized cartilage.
- Type XI collagen It is found in cartilage. Interact with types II and IX.
- Type XII collagen Present in tissues subject to high stresses, such as tendons and ligaments. Interact with types I and III.
- Type XIII collagen It is widely found as a protein associated with the cell membrane. Interact with types I and III.
- Type XIV collagen Non-fibrillary and very similar to type XII, it is present in the fetal epidermis and tendons.
- Collagen in fact, is the substrate of several enzymes of the family of matrix metalloproteases (MMPs) that play several of the main functions in the construction and renewal of tissues. Therefore, the determination of the collagenolytic activity in vivo of said enzymes, often called collagenases, is of great clinical and scientific interest.
- MMPs matrix metalloproteases
- the collagenolytic activity of some MMPs is partly derived from their tertiary structure depending on calcium and zinc. They are smaller than tropocollagen and have three distinct regions. One, called propeptide, has the ability to bind to collagen chains.
- the third region is the terminal carboxyl end, and consists of four ⁇ sheets that serve as propeller blades propelling the enzyme during the dismemberment of the Three strings in the alpha helix.
- the released alpha chains are susceptible to being digested by other enzymes such as pepsin and trypsin.
- chondroitin sulfate and hyaluronic acid are glycosaminoglycans present in connective tissue, and their catabolism is a signal of regeneration of connective tissue.
- Chondroitin sulfate or chondroitin sulfate is composed of a chain of disaccharides of N-acetylgalactosamide and N-glucuronic acid alternating.
- chondroitin chain can consist of more than 100 individual sugars, each of which can be sulfated in positions and in diverse numbers. Chondroitin sulfate gives cartilage its mechanical and elastic properties, and gives this tissue much of its resistance to compression. This is digested by a group of enzymes called sulfatases.
- Hyaluronic acid has a structural function, such as chondroitin sulfates. Of viscous texture, it exists in synovium, vitreous humor and connective tissue of numerous organisms and is an important glycoprotein in joint homeostasis. In humans it emphasizes its concentration in the joints, cartilage and skin. In an average man weighing 70 kilograms there can be a total amount of 15 grams of hyaluronic acid in his body, and a third of it degrades and synthesizes every day. It consists of complex carbohydrate chains, specifically about 50,000 disaccharides of N-acetylglucosamine and glucuronic acid per molecule and derives from the union of amino sugars and uronic acid.
- This chain is located forming spirals with an average molecular weight of 2 to 4 million. It has the property of retaining large amounts of water and adopting an extended conformation in solution, so they are useful when padding or lubricating. These properties are achieved thanks to the large number of hydroxyl groups and negative charges of this molecule, which allows, by the establishment of repulsive forces, that carbohydrate chains are relatively separated from each other.
- Hyaluronidase is the enzyme that hydrolyzes hyaluronic acid in the extracellular matrix
- the present invention also relates to the use of the compound with magnetic functionality as described in this patent application to manufacture an implant or gel to monitor an enzymatic activity involved in the regeneration of the extracellular matrix. Preferably, to monitor the regeneration of extracellular matrix that is part of the connective tissue, bone or of an organ.
- the compound with magnetic functionality can be used to make an implant or gel to monitor the biological integration of an implant in a human being or other living being. If the compound with magnetic functionality is found in the gel as described in this patent application, it can be used to monitor the biological integration of an implant. On the other hand, if the compound with magnetic functionality is in the implant as described in this patent application, it can preferably be used to monitor the biological integration of said implant.
- the present invention also relates to the implant comprising at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles as described in This patent application, to monitor the regeneration of connective tissue and / or the biological integration of an implant.
- the substrate is selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid, and the magnetic particles are superparamagnetic particles. Even more preferably, magnetite nanoparticles are linked through covalent bonds to the substrate.
- the present invention also relates to the gel comprising at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles as described. in this patent application, to monitor the regeneration of connective tissue.
- the substrate is selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid, and the magnetic particles are superparamagnetic particles. Even more preferably, the nanoparticles of Magnetite are bound through covalent bonds to the substrate.
- an implant comprising at least one compound with magnetic functionality as described in this patent application is not only useful for the evaluation of connective tissue regeneration, but also for the monitoring of therapeutic implants in which it is expected the appearance of de novo extracellular matrix.
- the implants object of the present invention suitable for use in monitoring the regeneration of connective tissue can be injectable gels, patches or dressings to be placed either on the surface of tissue to be regenerated or as grafts.
- connective tissue implants used clinically routinely or in the process of development. These implants generally comprise a combination of permanent and biodegradable biocompatible materials.
- biodegradable materials usually include components of the extracellular matrix produced by culture techniques, genetic recombination or extractions.
- the degradation, integration and corresponding replacement of the implant components by endogenous materials produced by the recipient organism is usually related to the invasion of mesenchymal cells and fibroblasts.
- the gels object of the present invention are suitable for use in the monitoring of regeneration of connective tissue in vitro, and can comprise the same materials mentioned in the previous paragraph for implants.
- biocompatible and biodegradable materials are polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyetheramides, polyorthoesters, polydioxanones, polyacetals, polykettals, polycarbonates, polyortocarbonates, polyphosphazenes, polyhydroxyate dihydroxy arctate dihydroxyarate dihydroxyacerates malic acid), poly (amino acids), poly (vinyl methyl ether), poly (maleic anhydride), chitin, chitosan, and copolymers, terpolymers, or polymers of greater poly-monomer or combinations thereof or mixtures thereof.
- polymers that may be comprised in the implants or gels of the present invention may comprise one or more recurring units selected from (siloxanyl) alkyl (meth) linear acrylates, (siloxanyl) alkyl (meth) branched acrylates, (siloxanyl) alkyl (meth) cyclic acrylates, (meth) acrylates containing silicone, (meth) acrylates containing fluoride, (meth) acrylates containing hydroxyl, (meth) acrylic acid, N- (meth) acryloylpyrrolidone, (meth) acrylamides, (meth) aminoalkyl acrylates, (meth) acrylates containing alkoxy groups, (meth) acrylates containing aromatic groups, (meth) glycidyl acrylate, (meth) tetrahydrofurfuryl acrylate, styrene derivatives containing silicone, styrene derivatives containing fluoride,
- biocompatible materials can be found, without excluding other materials, fibrin glue, polyglycolic acid, polylactic acid, polyethylene oxide gel, alginate or calcium alginate gel, poly- (2-hydroxyethyl methacrylate) , polyorthoester, polyanhydride, chitosan, gelatin, agarose, and other bioabsorbable and biocompatible materials.
- the implant or gel may comprise agar, agarose, gellan gum, arabic gum, xanthan gum, carrageenan, alginate salts, bentonite, Ficoll, Pluronic polyols, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, methyl cellulose, hydroxymethyl Cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, carboxymethyl chitosan, poly-2-hydroxyethyl methacrylate, polylactic acid, polyglycolic acid, gelatin, a plastic, or a combination thereof.
- Polysaccharides are a class of macromolecules of the general formula (CH 2 0) n which are also useful as implant or gel material in the present invention.
- Polysaccharides include several naturally occurring compounds, for example, agarose, alginate and chitosan.
- Agarose is a clear, heat-reversible hydrogel made of polysaccharides, mainly, alternating copolymers of 1,4, linked and 3,6-anhydrous.
- a preferred way to prepare the implant or gel is by glycation or cross-linking of extracellular matrix elements.
- type I type II collagen or a combination of both dissolved in acetic acid is used in a range of 1% to 5%, mixed with ribose or dextrose, stabilized at pH 7.4 and incubated at 4 ° C in phosphate saline solution and gelled at 37 ° C. It is possible to incorporate stabilized suspensions of the compound with magnetic functionality described in this patent application during any of the steps prior to gelling.
- chondroitin sulfate or hyaluronic acid in a concentration of the range of 1% to 5%, being able to be hyaluronic acid, previously stabilized by crosslinking.
- the gel may additionally comprise a biological or synthetic hydrogel, including alginate, cross-linked alginate, fibrin glue, fibrin clot, poly (N-isopropylacrylamide), agarose, chitin, chitosan, cellulose, polysaccharides, poly (oxyalkylene), a copolymer of poly (ethylene oxide) -poly (propylene oxide), poly (vinyl alcohol), polyacrylate, platelet-rich plasma clot (PRP), platelet-poor plasma clot (PPP) or mixtures thereof.
- a biological or synthetic hydrogel including alginate, cross-linked alginate, fibrin glue, fibrin clot, poly (N-isopropylacrylamide), agarose, chitin, chitosan, cellulose, polysaccharides, poly (oxyalkylene), a copolymer of poly (ethylene oxide) -poly (propylene oxide), poly (vinyl alcohol), polyacrylate, platelet-rich plasma
- the present invention also relates to the compound with magnetic functionality comprising a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles for manufacturing the implant as described in this patent application. , to monitor an enzymatic activity involved in the regeneration of the extracellular matrix in a human being or another living being in an implant. Preferably, to monitor the regeneration of connective tissue and / or the biological integration of the implant.
- the present invention relates to the compound with magnetic functionality comprising a substrate selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid, and a plurality of magnetic particles, to monitor an enzymatic activity involved in the regeneration of the extracellular matrix of the implant in a human being or other living being.
- a substrate selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid, and a plurality of magnetic particles
- a substrate selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid, and a plurality of magnetic particles
- the present invention also relates to a method for monitoring the regeneration of the extracellular matrix, preferably for monitoring the regeneration of connective tissue, which comprises using an implant or a gel comprising at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles as described in this patent application.
- the magnetic particles are bonded through covalent bonds to the substrate.
- the present invention relates to a method for monitoring the regeneration of the extracellular matrix, preferably to monitor the regeneration of connective tissue, which comprises using an implant or a gel comprising at least one compound with magnetic functionality which in turn comprises a substrate selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid, and a plurality of superparamagnetic particles as described in this patent application.
- the present invention also relates to a method for monitoring the biological integration of an implant in a human being or other living being as described in this patent application, which comprises using the compound with magnetic functionality which in turn comprises a substrate. of at least one enzyme involved in the regeneration of the extracellular matrix and a plurality of magnetic particles as described in this patent application.
- the magnetic particles are bonded through covalent bonds to the substrate.
- the present invention also relates to a compound with magnetic functionality comprising a substrate of at least one enzyme and a plurality of magnetic particles, characterized in that
- the magnetic particles have no coating or surface modification, or
- the magnetic particles are functionalized with carboxylic groups.
- the compound with magnetic functionality of the present invention allows to determine the enzymatic activity of one or more enzymes since said activity causes a measurable modification in its magnetic properties, in the magnetic properties of one or more of its degradation products, or in both.
- the magnetic particles as described in i) or ii) are bonded through covalent bonds to the substrate.
- the present invention relates to the compound with magnetic functionality comprising a substrate of at least one enzyme and a plurality of magnetic particles as described in this patent application, where the magnetic particles are superparamagnetic particles.
- the superparamagnetic particles may be ferrite nanoparticles, such as magnetite, maghemite, cobalt, silver or magnesium ferrites.
- the superparamagnetic particles are magnetite nanoparticles, it being especially preferable that the magnetite nanoparticles have a diameter less than 15 nm.
- the compound with magnetic functionality comprising a plurality of magnetic particles, preferably superparamagnetic particles, functionalized with carboxy groups and a substrate of at least one enzyme as described in this patent application, facilitates the binding of magnetic particles to amino groups present in the substrate of at least one enzyme.
- This compound with magnetic functionality is particularly of interest when the substrate comprises a significant number of amino groups, such as chondroitin sulfate and hyaluronic acid, two of the preferred substrates of this invention whose monomers possess amino groups.
- the present invention relates to a compound with magnetic functionality comprising a substrate of at least one enzyme and a plurality of magnetic particles, where the magnetic particles have no coating or surface modification.
- Coatings and surface modifications reduce the effect of certain magnetic particles such as ferrite particles on transverse (T2) and longitudinal (T1) relaxation times, whose measurement is the basis of the magnetic resonance currently used in medical applications.
- T2 transverse
- T1 longitudinal
- T2 transverse
- T1 longitudinal
- T2 transverse
- T1 longitudinal
- the magnetic particles contained in the compound with magnetic functionality described in this patent application do not present any coating or surface modification, allows to obtain a greater difference in the relaxation times measured before the compound digestion with magnetic functionality and after the aggregation of the magnetic particles as a result of enzymatic digestion.
- the present invention relates to the compound with magnetic functionality comprising a substrate of at least one enzyme and a plurality of magnetic particles, where i) the magnetic particles have no coating or surface modification, or ii) the Magnetic particles are functionalized with carboxylic groups as described in this patent application, where the substrate can be selected from the group consisting of protein, modified protein, polypeptide, modified polypeptide, glycoprotein, glycoaminglycan and a combination thereof.
- the substrate can be selected from the group consisting of collagen, fibrillin, elastin, laminin, osteacalcin, chondroitin sulfate, hyaluronic acid, osteanectin, osteopontin, gelatin and a combination thereof.
- the present invention relates to the compound with magnetic functionality comprising a substrate of at least one enzyme and a plurality of magnetic particles, preferably superparamagnetic particles, where i) the magnetic particles do not exhibit any coating or modification of surface, or ii) the magnetic particles are functionalized with carboxylic groups as described in this patent application, and where the substrate can be selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid.
- the present invention relates to the compound with magnetic functionality comprising a substrate of at least one enzyme and a plurality of magnetite nanoparticles that have no coating or surface modification, and where the substrate can be selected from group consisting of collagen, chondroitin sulfate and hyaluronic acid. More preferably, magnetite nanoparticles are linked through covalent bonds to the substrate.
- the present invention relates to a compound with magnetic functionality comprising magnetic particles, preferably superparamagnetic, functionalized with carboxylic groups, where magnetic particles tend to be added at physiological pH.
- the present refers to a compound with magnetic functionality comprising magnetic particles, preferably superparamagnetic, functionalized with carboxylic groups, where the magnetic particles have modifications only in part of their surface.
- the present invention relates to the compound with magnetic functionality comprising a plurality of magnetic particles immobilized on a substrate of at least one enzyme, where the magnetic particles have no coating or surface modification, and said compound is obtained by the procedure described below in this patent application.
- the present invention also relates to a method of obtaining the compound with magnetic functionality comprising a substrate of at least one enzyme and a plurality of magnetic particles that do not have any coating or surface modification as described in this patent application, characterized said procedure because it comprises:
- the magnetic particles are bonded through covalent bonds to the substrate.
- step a) of substrate modification substances are used that can subsequently be attached to the surface of the magnetic particles.
- This binding reaction is usually facilitated by the ionic dissociation of water on the surface of said particles, the substances used for the modification of the substrate being highly reactive in aqueous medium. Therefore, the modification of the substrate is preferably carried out under anhydrous conditions and organic medium, which makes it possible to minimize or prevent the reaction of the substance used to modify the substrate with water.
- this procedure allows the substrate of the enzyme to be bound to magnetic particles that are almost entirely magnetic core itself, thus obtaining a compound with much more sensitive magnetic functionality when determining the enzymatic activity.
- the present invention relates to the method of obtaining the compound with magnetic functionality which comprises immobilizing a plurality of uncoated magnetic particles or surface modification, more preferably superparamagnetic particles, on a substrate of at least one enzyme as described herein.
- the substrate preferably reacts with a compound selected from the group consisting of aminosilanes, aromatic diazonium salts, polymers, polyelectrolytes and bidentate complexes, preferably in an organic medium.
- Step a) of the process for obtaining the compound with magnetic functionality as described in this patent application can be carried out using a polymer selected from the group consisting of polyamines, polyethylenes, polydimides and polystyrenes.
- a bidentate complex selected from the group consisting of profirins and pyrimidines can also be used in this step 1) of substrate modification.
- dopamine conjugated with succinic acid in an aqueous medium can also be used at this stage of the process.
- step a) of the process can be carried out with aminosilanes in an organic medium with a maximum water content of 2%, preferably a maximum of 1%, which makes it possible to avoid or minimize contact of aminosilane with water, thus avoiding silanization or cross-linking reactions between aminosilane molecules.
- Aminosilanes belong to the group of alkoxysilanes.
- Compounds such as mica, glass or surface oxides can be silanized by containing hydroxyl groups replaceable by silane alkoxy groups resulting in the formation of covalent bonds -Si-O-Si.
- the use of aminosilanes allows the union of organic and inorganic elements.
- Alkoxysilanes are divided into three groups: aminosilanes, which have a secondary or tertiary amino group, glycidoxysilanes with an epoxide, and the third group is given by mercaptosilanes, which have thiols.
- the aminosilane used in step a) of the process for obtaining the compound with magnetic functionalization as described in this patent application can be selected from the group consisting of (3- aminopropyl) -triethoxysilane (APTES), (3-aminopropyl) -diethoxy-methylsilane (APDEMS), (3- aminopropyl) -dimethyl-ethoxy silane (APDMES) and (3-aminopropyl) -trimethoxysilane (APTMS).
- APTES (3- aminopropyl) -triethoxysilane
- APDEMS (3-aminopropyl) -diethoxy-methylsilane
- APIMES (3- aminopropyl) -dimethyl-ethoxy silane
- APITMS 3-aminopropyl) -trimethoxysilane
- the aminosilane used in step a) of the process of the present invention is (3-aminopropyl) -triethoxysilane (APTES) in organic medium.
- Step a) of reaction of the aminosilane, preferably APTES, with the substrate takes place in anhydrous organic solvent under conditions suitable to maintain the structural integrity of the substrate and facilitate dispersion thereof, preferably a protein.
- Such conditions may vary according to the structure of the substrate and are usually a function of the polarity and proticity of the solvent.
- the solvent is polar to preserve the bonds between prolines and hydroxyprolines.
- the solvent used in this step is acetonitrile.
- the structural integrity of the substrate can only be determined by experimental techniques such as spectrography, chromatography or circular dichroism.
- the functionalized compound obtained in step a) of the process of the invention can immobilize iron oxide particles or other ferrites without coatings or surface modifications, suspended in organic medium with a certain amount of dissolved water that facilitates the appearance of -OH ions. on the surface of said particles.
- the method of obtaining the compound with magnetic functionality of the present invention comprises an additional step, prior to step a), of activating the amino group of the aminosilane, preferably the aminosilane APTES, with an anhydride of acid and an organic base in an organic medium with a maximum water content of 2%, preferably a maximum of 1%.
- the amino group of the activated aminosilane in the form of anhydride can react in step a) of the process of the invention with amino groups present in the substrate.
- the activation of the amino group of the aminosilane can take place in the presence of glutaric anhydride and A /, A / -diisopropylethylamine, in an organic medium such as chloroform, acetonitrile, pentane, cyclopentane, hexane, cyclohexane, benzene, tuolene, 1 , 4-dioxane, diethyl ether, dichloromethane, tetrahydrofuran, ethyl acetate, acetone, dimethylformamide or dimethyl sulfoxide.
- an organic medium such as chloroform, acetonitrile, pentane, cyclopentane, hexane, cyclohexane, benzene, tuolene, 1 , 4-dioxane, diethyl ether, dichloromethane, tetrahydrofuran, ethyl
- the method of obtaining the compound with magnetic functionality of the present invention comprises an additional step, prior to step a), of activating the amino group of the aminosilane, preferably the aminosilane being APTES, with an aldehyde in an organic medium with a maximum water content of 2%, preferably a maximum of 1%.
- the activation of the amino group of the aminosilane is also achieved, facilitating its reaction in step a) of the process of the invention with carboxylic groups present in the substrate.
- the present invention also relates to the method of obtaining the compound with magnetic functionality comprising a plurality of magnetic particles, preferably superparamagnetic particles, functionalized with carboxyl groups and a substrate of at least one enzyme as described in this patent application. , wherein said process comprises the reaction of the functionalized magnetic particles with carboxylic groups with the substrate by means of aldehydes and / or carbodiimides.
- amino groups of the substrate can be modified, preferably a protein, to immobilize them in said particles functionalized with carboxylic groups on their surface, for example, using dimercaptosuccinic acid.
- This method is carried out in two stages: a1) the union between 3-thiophenoacetic acid and magnetic particles, preferably magnetite nanoparticles, occurs at 80 ° C in acetonitrile as solvent through the interaction with potassium permanganate on the surface of iron oxide; b1) after this first modification, the particles are placed in a solution with meso-2,3-dimercaptosuccinic acid which is immobilized on their surface.
- magnetic particles functionalized with carboxy groups can be obtained from modifying their surface with aminosilane previously activated with an aldehyde, in a process comprising two steps:
- step b2) bind the civated aminosilane with the aldehyde according to step a2) to the magnetic particles by interacting between the silane groups and the hydroxyl groups on the iron oxide surface.
- these particles functionalized with carboxylic groups can be linked by covalent bonds to the substrate, in particular to the amino groups present in said substrate.
- the activation of the amino group of the aminosilane can take place in the presence of glutaric anhydride and A /, A / -diisopropylethylamine, in an organic medium such as chloroform, acetonitrile, pentane, cyclopentane, hexane, cyclohexane, benzene, tuolene, 1 , 4-dioxane, diethyl ether, dichloromethane, tetrahydrofuran, ethyl acetate, acetone, dimethylformamide or dimethyl sulfoxide.
- an organic medium such as chloroform, acetonitrile, pentane, cyclopentane, hexane, cyclohexane, benzene, tuolene, 1 , 4-dioxane, diethyl ether, dichloromethane, tetrahydrofuran, ethyl
- the activation of the amino group of the aminosilane preferably the aminosilane being APTES, with an aldehyde in an organic medium with a maximum water content of 2%, preferably a maximum of 1%.
- the modification of the surface of the magnetic particles is preferably performed by mixing the magnetic nanoparticles in a solution of ethanol or methanol with between 0.1% and 1% of activated aminosilane, and finally between 0% and 5% of NH solution 3 between 10% and 50%. Following this protocol it is expected to obtain the total surface coverage of the nanoparticles in a time of 24 h and a coverage that can be partial in less time.
- the magnetic particles are only partially functionalized with carboxylic groups. In this way the aggregation of these particles at physiological pH is facilitated.
- step a1) is carried out in a time less than 30 minutes or at a temperature less than 80 ° C. In an even more preferred embodiment of the invention this time is between 1 minute and 15 minutes. In yet another preferred embodiment of the invention this time is less than 5 minutes. In another preferred embodiment of the invention the temperature is between 10 ° C and 60 ° C.
- step a2) is carried out in less than 24 hours. In an even more preferred embodiment of the invention this time is less than 12h. In yet another preferred embodiment of the invention this time is between 1 h and 5 h.
- step a2) is performed with a volume concentration of NH 3 of less than 10%.
- the present invention also relates to a product comprising at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles, where i) the magnetic particles have no coating or surface modification, or ii) the magnetic particles are functionalized with carboxylic groups as described in this patent application, wherein said product is selected from the group consisting of an implant, a gel, a pharmaceutical composition and a contrast agent.
- the product comprising the compound with functionality Magnetic as described in this patent application may be a pharmaceutical composition and further comprise at least one pharmaceutically acceptable excipient.
- a preferred route of administration of the compound with magnetic functionality as described in this patent application, without excluding other possible forms of administration, is intravenous administration, preferably local.
- a detailed list of possible forms of administration of the possible formulations derived from this invention is given by John M. Walker, Macromolecular drug delivery: methods and protocols, Volume 480, Methods in molecular biology, Springer protocols.
- the present invention relates to an encapsulated pharmaceutical composition
- an encapsulated pharmaceutical composition comprising the compound with magnetic functionality as described in this patent application and at least one pharmaceutically acceptable excipient, this excipient suitable for allowing the release of the compound. with magnetic functionality at the site where the reaction takes place between the modified substrate and at least one of the enzymes with which it reacts.
- the present invention relates to an encapsulated composition
- an encapsulated composition comprising an active ingredient, the compound with magnetic functionality as described in this patent application and at least one pharmaceutically acceptable excipient.
- this encapsulated composition can be used to evaluate the effectiveness of administration of said active ingredient.
- the present invention relates to a pharmaceutical composition that can comprise a compound with magnetic functionality which in turn comprises a plurality of magnetite nanoparticles, preferably without coatings or surface modification, immobilized on a substrate selected from the group that It consists of collagen, chondroitin sulfate and hyaluronic acid. More preferably, magnetite nanoparticles are linked through covalent bonds to the substrate.
- the present invention relates to an implant or a gel comprising at least one compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles, where i) the magnetic particles do not present any coating or surface modification, or ii) The magnetic particles are functionalized with carboxylic groups as described in this patent application.
- the implant or gel comprises the compound with magnetic functionality which in turn comprises a substrate involved in the regeneration of the extracellular matrix as described above in this patent application, and a plurality of magnetic particles that have no coating. or surface modification as described in this patent application.
- the present invention relates to the implant or gel comprising the compound with magnetic functionality which in turn comprises a substrate selected from the group consisting of collagen, chondroitin sulfate and hyaluronic acid, and a plurality of magnetic particles , preferably magnetite nanoparticles, which do not exhibit any coating or surface modification as described in this patent application. More preferably, magnetite nanoparticles are linked through covalent bonds to the substrate.
- the implant or gel comprises the compound with magnetic functionality which in turn comprises a substrate involved in the regeneration of the extracellular matrix as described above in this patent application, and a plurality of magnetic particles. which do not have any coating or surface modification, and said compound with magnetic functionality is obtained by the procedure described in this patent application.
- the present invention also relates to the use of the compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles, where i) the magnetic particles do not exhibit any coating or surface modification, or ii) the magnetic particles are functionalized with carboxylic groups as described in this patent application, to manufacture a product as described in this patent application to determine or discriminate the enzymatic activity of one or more enzymes.
- the present invention relates to the use of the compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles as described in this patent application, to manufacture a product as described in this patent application to detect a disease or disorder associated with the enzymatic activity of at least one enzyme.
- the disease or disorder can be selected from the group consisting of rheumatitis, arthritis, injury, connective tissue related disease, Dupuytren's disease, Peyronie's disease, collagen-related disease, steatosis, fibrosis, cirrhosis, metastasis, regeneration of tissues, cancer, coronary heart disease, liver disease, metabolic disease, infection and inflammatory disease.
- MMPs plays a part in diseases such as arthritis, rheumatitis, conditions related to the growth of connective tissue as well as Dupuytren or Peyronie's diseases, the conditions that lead to liver fibrosis, cirrhosis or cardiovascular, obstructions of the angina of the unstable type.
- diseases such as arthritis, rheumatitis, conditions related to the growth of connective tissue as well as Dupuytren or Peyronie's diseases, the conditions that lead to liver fibrosis, cirrhosis or cardiovascular, obstructions of the angina of the unstable type.
- Woessner JF Jr. in Matrix metalloproteinases and their inhibitors in connective tissue remodeling, FASEB J. 1991 May; 5 (8): 2145-54 and by Somers KD, Dawson DM in Fibrin deposition in Peyronie's disease plaque J Urol. 1997 Jan; 157 (1): 311-5.
- the present invention also relates to the use of the compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles, where i) the magnetic particles do not exhibit any coating or surface modification, or ii) the magnetic particles are functionalized with carboxylic groups as described in this patent application, to manufacture the pharmaceutical composition described above to detect a disease or disorder associated with the enzymatic activity of at least one enzyme.
- the disease or disorder is selected from the list included above.
- the extracellular matrix and a thick fibrous layer provide stability to the atherosclerotic plaque.
- the unstable plate has a thin fibrous layer, a high number of inflammatory cells, a large lipid nucleus and can induce thrombus formation.
- the synthesis of collagen by smooth muscle cells is stimulated by growth factors, such as transforming growth factor-beta (TGF- ⁇ ). Inflammation in the plaques, with the accumulation of macrophages and T lymphocytes, leads to the release of MMPs, which digest the collagen and cause the thinning of the fibrous layer.
- TGF- ⁇ transforming growth factor-beta
- necrotic lipid nucleus grows as a result of the accumulation of lipids in the extracellular matrix, the death of macrophages loaded with lipids, and possibly due to the accumulation of erythrocyte membranes after intraplate hemorrhage of the vasa vasorum.
- Oxygen radicals are generated from various sources, including NADPH oxidase and inflammatory cells, oxidize low density lipoproteins (LDL) and cause cell necrosis. Repetitive cycles of plaque rupture and healing, which can be clinically silent, produce layers in the plaque.
- MMPs act in the extracellular space and at physiological pH.
- the matrix metalloprotease superfamily includes MMP 1 or interstitial collagenase, an enzyme specialized in the initial division of fibrillar collagen generally resistant to protease that confer resistance to the fibrous layer of atheroma. Other members of the matrix metalloprotease family, such as gelatinases, can catalyze the subdivision of collagen fragments.
- Stromelysins can activate other members of the MMP family and can degrade a wide range of matrix components, including the protein backbone networks of proteoglycan molecules. Stromelysins and one of the gelatinases (gelatinase B or 92 kDa gelatinase) can also break elastin, an additional structurally important component of the vascular extracellular matrix.
- the present invention relates to the use of the compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles, where i) the magnetic particles have no coating or surface modification, or ii) the magnetic particles are functionalized with carboxylic groups as described in this patent application, to manufacture a contrast agent to determine the contrast Enzymatic activity of MMPs in coronary plaque.
- the substrate can be a protein and it can be selected from the group consisting of collagen, fibrillin and elastin.
- MMPs are also closely related to certain liver diseases. Liver fibrosis involves multiple cellular and molecular events that lead to the deposition of excess extracellular matrix proteins and even a distortion of the liver's normal architecture. Etiologies include chronic viral hepatitis, fatty liver due to alcohol abuse, non-alcoholic steatosis and drug toxicity. Overexpression of MMPs is one of the molecular markers that can differentiate hepatic steatosis from fibrosis or cirrhosis. In addition, one type of collagenase (MMP-13) and other MMPs have a transiently increased activity in the first stage of liver fibrosis and a reduced activity in advanced fibrosis.
- MMP-13 collagenase
- MMP-1, MMP-8 and MMP-13 MMPs in general cannot break type I collagen.
- MMP-2, MMP-3 and MMP-9 can digest type IV collagen and the enzymatic activity of These MMPs decrease progressively with the onset of cirrhosis.
- mRNA expression of these enzymes include those with collagenolytic activity
- TIMP tissue inhibitors of Metalloproteases
- hepatic fibrosis regression is mediated by the decrease in TIMP expression and involves the degradation of fibrillar collagen by a combination of MMP-1 and gelatinase A, in addition to interstitial collagenase.
- Kupffer cells and lipocytes play a central role in the synthesis of MMP and TIMP.
- Nano- and micro-particles are usually markedly retained by Kupffer cells in the liver.
- Administration of collagen modified to have magnetic functionality as described in this patent application is useful for evaluating various liver conditions by determining the collagenolytic activity of certain MMPs in the liver. This modified collagen produces a contrast effect caused by different relaxation times for water protons that are in the vicinity of magnetic particles anchored to the modified collagen with respect to their distant counterparts. This effect on relaxation is even greater if the magnetic particles are added as a result of enzymatic degradation. This difference is even more significant if the magnetic particles do not carry surface modifications.
- the degree of such effect a greater contrast in the magnetic resonance image is an expression signal of the MMPs.
- This increase in the contrast effect of the magnetic resonance signal can be measured over time by different parameters used in magnetic resonance image measurements such as signal intensity, weighted images of T1 or T2, the calculation of diffusion parameters, saturation images or a combination of them, without excluding other NMR parameters not listed in this application.
- signal intensity weighted images of T1 or T2
- diffusion parameters saturation images or a combination of them
- collagen modified to have magnetic functionality by immobilization of magnetic particles As described above, it is administered to the liver, compared to the normal liver, in the final stages of steatosis or hepatosteatosis and early fibrosis can be observed by analytical techniques such as magnetic resonance a greater contrast effect, but during the later stages of fibrosis or cirrhosis this contrast effect is more moderate.
- MMPs are also significantly higher in patients with liver metastases.
- cancer the balance between the production and activation of MMPs and their inhibition by TIMPs is a crucial aspect of invasion and metastasis.
- MMPs are synthesized in tissues and filtered through the bloodstream. It has been observed that in cancers, colorectal, breast, prostate and bladder, most patients with severe disease have increased plasma levels of gelatinase B. In particular, in patients with advanced colorectal cancer, a correlation between high levels of either gelatinase B or TIMP complex has been observed and was associated with shorter survival. Therefore, it is within the scope of the invention to use compounds with magnetic functionality as substrates to evaluate the expression and / or enzymatic activity and its consequences in cancer and, in general, the activity of MMP and other enzymes in organs, tissues or Other body compartments.
- the present invention relates to the use of the compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles, where i) the magnetic particles do not exhibit any coating or surface modification , or ii) the magnetic particles are functionalized with carboxylic groups as described in this patent application, to manufacture an implant or gel to monitor an enzymatic activity involved in the regeneration of the extracellular matrix, preferably in the regeneration of cartilage.
- the present invention relates to the use of the compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles, where i) the magnetic particles do not exhibit any coating or modification surface, or ii) the magnetic particles are functionalized with carboxylic groups as described in this patent application, to manufacture an implant to monitor the biological integration of the implant in a human being or other living being.
- the compound with magnetic functionality described in this patent application comprising magnetite nanoparticles functionalized with carboxylic groups and immobilized in chondroitin sulfate, is added to an aqueous mixture comprising an additional amount of chondroitin sulfate, or another suitable glycosoaminglicac or glycoprotein to make a cartilage implant.
- a gel is obtained that can be incorporated into a cartilage implant and act as a reporter of the activity of chondroitin sulfate or sulfatase hydrolases, which play a role in the regeneration of cartilage.
- this gel can also be used as a reporter of chondroitin sulfate or sulfatase hydrolase activity in vitro.
- the compound with magnetic functionality comprising a plurality of magnetic particles immobilized on a substrate of at least one enzyme as described in this patent application
- said compound allows to determine the activity enzymatic of one or more enzymes that react with said substrate. This determination is made by measuring the variation caused by said enzymatic reaction in a parameter associated with the magnetic properties of the compound with magnetic functionality, at least one of its reaction products, or a combination of both.
- the present invention relates to the use of:
- - compound with magnetic functionality which in turn comprises a substrate of at least one enzyme and a plurality of magnetic particles, where i) the magnetic particles have no coating or surface modification, or ii) the magnetic particles are functionalized with carboxylic groups as described in this patent application;
- the present invention relates to the use of the compound with magnetic functionality as described in this patent application, to determine the variation in the magnetic property caused by the enzymatic reaction by a technique selected from the group consisting of in nuclear magnetic resonance (NMR), electronic paramagnetic resonance (EPR), magnetometry including vibrational magnetometry (MVS) and quantum superconductive interference equipment (SQUID) magnetometry ), Móssbauer spectrometry, X-ray magnetic circular dichroism (XMCD), ferromagnetic resonance imaging (FMR), Kerr Magnetic Optical Effect (MOKE), Brillouin Light Dispersion (BLS) , electromagnetic inductance, atomic force microscopy, magnetorelaxometry and a combination of them.
- NMR nuclear magnetic resonance
- EPR electronic paramagnetic resonance
- MVS vibrational magnetometry
- SQUID quantum superconductive interference equipment
- Some of these techniques can be used to determine in vitro or ex vivo the existence of enzymatic activity by establishing spectra and curves of previously dissected or lyophilized samples containing modified substrates to have magnetic functionality and observing changes in said spectra or curves depending on of the state of aggregation of the magnetic particles present in modified substrates to have magnetic functionality before and after their exposure to a biological agent. Below is a brief description of them.
- EPR spectroscopy measures the energy differences between the states caused by the splitting that is generated by placing a system with missing electrons in an external magnetic field (Zeeman effect).
- the difference in energies between two states will be of the form g ⁇ BHZ, where g is the Landé factor, ⁇ is the magnet of Bohr and H is the applied magnetic field.
- the so-called resonance condition to obtain a resonance peak in the spectrum is:
- this field H z will be the resonance field.
- the Lande factor g can be cleared. This g factor can be very useful when identifying the sample, but it is not unique, it will depend on the frequency chosen for the radiation. Other data thrown by the spectrum such as intensities, number of lines, distance between them, their shape and width among others also constitute other very useful sources of information when identifying and characterizing the sample. In this way, the electrons of the magnetic particles, especially those that are closest to their surfaces, will produce different resonance signals depending on the state of aggregation of the magnetic particles which result in changes in the spectrum.
- MVS and SQUID directly measure the magnetic fields based on magnetization of a sample and determine variation curves.
- Móssbauer spectroscopy is a spectroscopic technique based on the emission and resonant absorption of gamma rays in solids. This is similar to nuclear magnetic resonance (NMR) spectroscopy in that it probes nuclear transitions and is thus sensitive to similar electron-core interactions as chemical NMR causes.
- NMR nuclear magnetic resonance
- the emitting element to characterize compositions with Fe 57 is usually Co 57 .
- there are three types of nuclear interactions that are observed isomeric displacement, quadrupole division, and hyperfine division.
- the hyperfine division (also Zeeman division) is a result of the interaction between the nucleus and any surrounding magnetic field.
- this divides the single peak into six non-degenerated peaks.
- the hyperfine division usually measured as the distance between the outermost part of these six peaks. Hyperfine division is especially important in Móssbauer spectroscopy of iron-containing compounds, which are often ferromagnetic or antiferromagnetic, resulting in strong internal magnetic fields.
- the relative intensities of the various peaks reflect the relative concentrations of the compounds in the sample and can be used for semi-quantitative analysis.
- the spectra can provide information on the size of the crystalline and granular structures of a material containing iron.
- Circular X-ray magnetic dichroism is the difference between two X-ray absorption spectra, taken by applying a magnetic field, one with circularly polarized light on the right (RCP) and one on the left (LCP).
- RCP circularly polarized light on the right
- LCP left
- the greatest advantage of this technique is its sensitivity to each element, which allows magnetically characterizing specific elements and finding magnetic moments of minor elements or diluted in a matrix. Since the X-ray absorption measure is carried out for energies corresponding to the absorption edge of a specific element, only the particular contribution of said element is observed. This characteristic is particularly interesting when dealing with nanoparticles, since it allows the contribution of other elements or possible impurities to be separated from the total magnetization.
- the effect is based on the fact that the absorption of X-rays by the material will be dependent on the polarization of light and the spin and orbital moments of electrons.
- the XMCD signal is obtained. It is then possible to calculate the magnetic moment of an electron by of the so-called sum rules. This technique also allows the spin and orbital components to be separated at the magnetic moment.
- ferromagnetic resonance (FMR) technique a magnetic field is applied parallel to the plane of a film containing the sample.
- the sample is placed in a goniometer that allows to rotate the plane of the same with respect to the direction of the field.
- the resonance field, HR, and peak-to-peak line width, ⁇ are obtained as functions of the field angle in the plane, the temperature and the thickness of the film.
- the plane of polarization may rotate slightly. This effect is known as the magneto-optical Kerr or MOKE effect which is widely used in the characterization of thin films of ferromagnetic materials.
- the sample is placed is a goniometer that allows to rotate the plane of the same with respect to the direction of the field, but unlike this, an estimate of the area of a hysteresis curve is obtained from the measurement of the refractive coefficients for the different orientation angles of the sample.
- Brillouin dispersion is an optical phenomenon that can be observed when there are magnetic irregularities in a film or medium that is traversed by an incident beam.
- these analytical techniques allow the detection of enzymatic activity in vivo and can be selected from the group consisting of magnetometry and nuclear magnetic resonance.
- this analytical technique is magnetic resonance imaging.
- the present invention relates to the use of the compound with magnetic functionality as described in this patent application, where the enzymatic reaction causes a variation in the magnetic properties, preferably a at least partial change from superparamagnetism to paramagnetism, detectable by determining a parameter selected from the group consisting of signal intensity, longitudinal relaxation time (T1), transverse relaxation time (T2), diffusion parameter, response signal to a first series of pulses, saturation signal I and a combination of them.
- the variation in the properties Magnetic caused by the enzymatic reaction can be determined by a parameter selected from the group consisting of longitudinal relaxation time (T1), transverse relaxation time (T2) and the ratio between T1 and T2.
- said variation can be determined by the radius between T1 and T2.
- the variation in the magnetic properties caused by the enzymatic reaction can be determined by analyzing said parameter before and after the enzymatic reaction takes place as described in this patent application.
- the parameter is analyzed before and after the enzymatic reaction takes place between the compound with magnetic properties object of the invention comprising a substrate of one or more enzymes, and one or more of these enzymes.
- Measurement methods based on magnetic resonance are suitable indirect methods for measuring variations in the magnetic properties of compounds with magnetic functionality, of at least one of its degradation products or a combination of these.
- nuclear resonance methods the relaxation times of the response to the effect of the application of a radiofrequency (RF) perpendicular to an intense magnetic field are measured. These relaxation times are called T1 and T2, and represent the characteristic times of the relaxation of water protons as a result of the disappearance of a magnetic field in the longitudinal plane to the applied RF and the reappearance of the magnetic field strength in perpendicular to the plane of the RF applied, respectively, as a consequence of the elimination of such RF.
- RF radiofrequency
- ⁇ 0 is the precession frequency
- ⁇ is a phase constant.
- Longitudinal relaxation reflects a loss of energy, such as heat, from the system to its surrounding network, and is primarily a measure of the bipolar coupling of proton moments to its surroundings.
- the relaxation in the xy plane is relatively rapid, and is driven by the loss of phase coherence in proton precession due to their magnetic interactions with each other and with other fluctuations of the magnetic moments in the tissue.
- a lag can also be affected by local inhomogeneities in the longitudinal scope of application, resulting in the replacement of T2 in the second equation for the shorter relaxation time, T2 *:
- ⁇ 0 is the variation in the field produced either through distortions in the homogeneity of the field applied itself, or by local variations in the magnetic susceptibility of the system.
- This variation of ⁇ 0 can be precisely caused by magnetic particles, which cause a significant predominance over the possible local factors of inhomogeneity of the B 0 field.
- said differences resulting in ⁇ 0 caused by changes in the state of distribution or aggregation of magnetic particles which are first immobilized on substrates or other macromolecules of interest the cause of the signal detected as a consequence of degradation or the metabolic use of said substrates or other macromolecules of interest.
- the present invention relates to the use of the compound with Magnetic functionality as described in this patent application, where the variation in a magnetic property is indicative of at least one physical phenomenon selected from the group consisting of:
- the effect of the alignment of magnetic moments of magnetic particles can vary significantly as a result of their grouping or distribution. It can be understood from two factors 1) the effects of thermal or kinetic agitation, as explained above, and 2) the average time and energy required to respond to an applied external magnetic field as explained below.
- a case of special interest is one in which the magnetic particles are superparamagnetic and tend to aggregate as a consequence of the variation of such conformations.
- the resulting magnetic aggregate which does not necessarily have to be superparamagnetic, has magnetic properties that differ measurably from the magnetic properties of the original magnetic particles. Therefore, when determining variations in magnetic properties, a signal of an enzymatic effect can be detected.
- magnetite nanoparticles of less than 15 nm in diameter, they behave as superparamagnetic when suspended in aqueous solutions at biological temperatures, but their behavior becomes paramagnetic if they are added forming clusters of larger diameter.
- ⁇ 0 is the magnetic permeability of the medium
- the susceptibility of the materials depends not only on the temperature, but also on the intensity of the magnetic field (H), which gives rise to the characteristic sigmoidal shape of the MH curve, with M approaching a saturation value at large values of H
- H intensity of the magnetic field
- a hysteresis curve often appears that is an irreversibility in the magnetization process related to the spin of the magnetic domains in the walls of the impurities or granulation limits within the material itself, as well as to intrinsic effects such as the magnetic anisotropy of the crystal lattice. This results in the MH curves generating hysteresis loops.
- the shape of these cycles is determined in part by the size of the particles: in large particles (of the order of myras or more) it is a fundamental state of several domains which leads to a narrow hysteresis cycle, since it requires relatively little Country energy make the walls of the domains move. In smaller particles the basal state of the single domain is what determines the existence of hysteresis In even smaller sizes (of the order of tens of nanometers or less) superparamagnetism is observed, where the magnetic moment of the particle is free to fluctuate in response to thermal energy, while relative individual atomic moments maintain their orderly state. This causes sigmoidal MH curves, lacking hysteresis. Even for superparamagnetic particles arranged in bulk, their magnetic moments interact affecting the MH curves (even in some cases hysteresis can be observed) as well as relaxation times resulting in other magnetic and optical effects.
- FIG. 2 depicts the M-H curve of type I collagen functionalized with magnetite superparamagnetic nanoparticles with a diameter of 10 nm in 10 ml my saline suspension immobilized in agarose.
- Figure 3 depicts the HM curve of a similar suspension immobilized on agarose after incubation with type I collagenase for 12 hours at 37 ° C.
- a slightly open curve can be seen, however, the HM curve of the figure. 2 does not show hysteresis.
- This magnetic behavior is due to the interaction between the magnetic moments of the nanoparticles as a whole after their aggregation as a result of the collagenolytic activity of collagenase.
- the collagenase hydrolyzes the modified collagen, the alpha chains separate and the anchored magnetic nanoparticles tend to aggregate as a consequence of thermal movement inducing the magnetic coupling between the magnetic domains of the same magnetic ones as they are added.
- a preferred technique to perform the measurement is magnetic resonance, where the accumulation or dispersion of magnetic particles can be measured by changes in the relaxation times and, therefore, also in the contrast effect of such magnetic particles.
- the collagen may be provided, either as isolated ⁇ chains or both naturally occurring and synthetic fragments of the protocol following a similar process to immobilize magnetic particles that can be made in ⁇ chains or isolated monomers.
- the ⁇ chains can be induced to adopt a triple helix structure, as an example, with the suspension or dissolution in them an acid medium treated with pepsin, washing, filtering, washing, filtering and collecting the precipitates.
- Figure 4 shows a scheme of a modified collagen tripeptide (A), functionalized with magnetite nanoparticles (B).
- FIGURES The drawing is not in scale and the distribution of magnetite nanoparticles is not necessarily coincident with a real distribution.
- Figure 5 shows the effect of collagenolytic activity on the distribution of magnetic nanoparticles first immobilized in collagen after the collagen is digested by collagenases.
- Figure 1 shows the evolution in nuclear magnetic relaxation as a function of particle size or state of aggregation, according to an embodiment of the invention. You can see the magnetic relaxation, measured in ms- 1 , at different concentrations, measured in mM of iron per liter, produced by three different particle suspensions: 10 nm dispersed by sonication (triangles), 50 nm dispersed by sonication (squares) and 10 nm aggregates (rhombuses).
- Figure 2 depicts the MH magnetization curve of type IV collagen modified with magnetite superparamagnetic nanoparticles with a diameter of 10 nm in 10 ml of saline suspension and immobilized in agarose, according to an embodiment of the invention. The horizontal axis represents the applied H field and the vertical axis to the magnetization M measured in amps per revolution per meter.
- FIG. 3 shows the magnetization curve HM a suspension prepared as described for Figure 2 agarose - immobilized after incubation with collagenase for 12 hours at 37 0 C, according to an embodiment of the invention.
- the horizontal axis represents the applied H field and the vertical axis to the magnetization M, both measured in amps per revolution per meter.
- Figure 4 shows a schematic of a triple helical region of modified collagen (A), functionalized with magnetite nanoparticles (B), in accordance with an embodiment of the invention.
- Figure 5 shows the effect of collagenolytic activity on the distribution of magnetic nanoparticles first immobilized in collagen and after said collagen is digested by collagenases, according to an embodiment of the invention.
- Figure 6 shows the comparison of T2 maps seen through its axial axis of two sample tubes (C) and (D), in which 0.5 mg of collagen modified to have magnetic functionality by immobilizing magnetite particles 10 nm in diameter without surface modifications in 10% of its lysines.
- said modified collagen is immobilized in a 1 ml suspension of 10% agarose in 10 mM solution of calcium chloride and 400 mM of sodium chloride at pH 7.4 with 1 mg of collagenase being added only in tube C.
- Tube D being a control. Both tubes were incubated for 1 h at 37 ° C.
- the average of the T2 maps of both tubes is 168 ms for (C) and 150 ms for (D), according to an embodiment of the invention.
- FIG. 7 shows the comparison of T2 maps seen through its axial axis of two sample tubes (E) and (F), in which 0.5 mg of unmodified collagen as a control.
- said collagen is immobilized in a suspension of 10% agarose in 1 ml of 10 mM solution of calcium chloride and 400 mM of sodium chloride at pH 7.5 with 1 mg of collagenase being added only in the tube (AND).
- the tube (F) being a control. Both tubes were incubated for 1 h at 37 ° C.
- the average of the T2 maps of both tubes is 191 ms for (E) and 189 ms for (F), these relaxation times being different from those observed in the collagen modified from Figure 6, according to an embodiment of the invention. Differences in relaxation times on T2 maps is difficult to perceive visually as seen in this figure.
- Figure 8 schematically shows the activation of (3-aminopropyl) -triethoxysilane (APTES) (G), with glutaic anhydride (H) mediated by ⁇ , ⁇ -diisopropylethylamine (DIEA) (I), to facilitate binding to a group amino belonging to a collagen lysine, according to an embodiment of the invention.
- APTES (3-aminopropyl) -triethoxysilane
- H glutaic anhydride
- DIEA ⁇ -diisopropylethylamine
- Figure 9 schematically shows the modification of an amino group belonging to a collagen lysine (K), by linking modified APTES (J) as shown in Figure 8, mediated by diisopropyl carbodiimide (PCD DI) (L) , to allow anchoring of a magnetite particle without surface modifications in the modified collagen (M), in accordance with an embodiment of the invention.
- K collagen lysine
- PCD DI diisopropyl carbodiimide
- Figure 10 schematically shows the binding of an amino group belonging to a polylysine monomer (N) with activated APTES (J) as shown in Figure 8, mediated by PCD DI (L), to produce APTES modified polylysine ( ⁇ ) to facilitate anchoring to a nanoparticle, in accordance with an embodiment of the invention.
- Figure 1 1 shows the modification of a magnetite particle without modifications of surface (O), with at least one modified polylysine ( ⁇ ) as shown in Figure 10, to produce a modified magnetic particle with a polylysine (R), which can be linked by carbodiimides to an endogenous collagen lysine , according to an embodiment of the invention.
- Figure 12 shows the modification of the n-acetylamino group of a chondroitin sulfate monomer (S), by linking N- (3-Dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (EDC) (T), to allow the anchoring of a Magnetite particle modified on its surface with dimercaptosuccinic acid (U), according to an embodiment of the invention.
- S chondroitin sulfate monomer
- EDC N- (3-Dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride
- U dimercaptosuccinic acid
- APTES is first bound to its lysines.
- APTES is activated with glutaric anhydride to form a complex. This reaction is carried out with N, N-diisopropylethylamine (DIEA).
- DIEA N, N-diisopropylethylamine
- APTES, glutaric anhydride and IDEA dissolve in acetonitrile in a ratio of 1: 1: 3 and stir for 24 hours in a dry atmosphere.
- the collagen is dissolved in acidic medium with a diffractant such as mannitol and freeze dried.
- the lyophilized collagen is suspended and homogenized in acetonitrile, the resulting mixture is added to the activated APTES in a 28: 1 ratio thereto, diisopropyl carbodiimide (DIPCD) is added in a 1: 1 ratio and set to Mix in a dry atmosphere for another 48 hours.
- DIPCD diisopropyl carbodiimide
- Acetonitrile is replaced by ethanol by evaporation and surpluses of APTES, other compounds than collagen, are removed by repeated centrifugation and the preparation is suspended again in ethanol.
- Magnetite particles of less than 15 nm in diameter in suspension in a basic, generally aqueous medium, are mixed in ethanol in an ethanol / water ratio of at least 98: 1 and sonicated.
- Excesses can be eliminated through columns, gradient centrifugation or magnetic separation, dialyzed and lyophilized.
- the resulting formulation is useful for the detection of collagenolytic activity in vivo, in vitro or ex vivo. Due to the triple helix structure of the collagen, once the collagen modified to have magnetic functionality is degraded by a collagenase, the magnetic particles originally immobilized in it will tend to aggregate or disperse based on their basal distribution along the chains of the collagen
- APTES is first bound to polylysine to then anchor the modified particles.
- This modified polylysine can bind to collagen by crosslinking mediated by the enzyme lysyl oxidase.
- the polylysine is activated with glutaric anhydride prior to its binding to APTES.
- This activation reaction is carried out by dissolving APTES, glutaric anhydride and N, N-diisopropylethylamine (IDEA) in acetonitrile in a ratio of 1: 1: 3. Subsequently, it is stirred for 24 hours in a dry atmosphere.
- the polylysine is suspended in acetonitrile, the resulting mixture is added to the activated APTES in a 1: 1 ratio thereto, together with PCD DI in a 1: 1 ratio and mixed in a dry atmosphere for another 48 hours.
- Acetonitrile is replaced by ethanol by evaporation and surpluses of APTES and other compounds other than modified polylysine are removed by repeated centrifugation and re-suspension in ethanol.
- Magnetite particles of less than 15 nm in diameter in suspension in an aqueous basic medium, mixed with ethanol in an ethanol / water ratio of at least 98: 1. Sonic, added to the ethanol-modified polylysine mixture previously obtained and mix again in a dry atmosphere for another 48 hours. Ethanol is replaced by water by evaporation, stabilized at a basic pH to maintain the stability of the modified particles.
- Magnetic particles modified with polylysines bind to collagen by transforming the lysines into allisins by the enzyme lysyl oxidase which also facilitates allisin-alisin bonds.
- the resulting gel is semi-solid and, once implanted, capable of replacing connective tissue. Implantation of said implant implies the invasion of it by fibroblasts which secrete collagenases and in turn degrading the implant's own collagen and replacing it with collagen with a morphology similar to that of the surrounding tissue.
- the previous degradation of collagens causes the aggregation of the magnetic particles which can be detected by means of weighted magnetic resonance imaging maps.
- EXAMPLE 3 CHANGES OF CONDROITIN SULFATE CHAINS WITH MAGNETIC NANOPARTICLES FUNCTIONED WITH CARBOXYL GROUPS TO BE INCLUDED IN CARTILAGO IMPLANTS
- 300 microliters of APTES, 414 microliters of DIEA and 16 milligrams of glutaric anhydride are mixed in 20 milliliters of acetonitrile for 24 hours.
- 250 ml of ethanol with a 99% min purity 2 ml of 10 nm magnetite particles suspended in acid solution with an approximate iron concentration of 16 mg / ml and 10 ml of 30% NH 3 solution are added.
- the mixture is left under stirring for 3 hours and the ethanol is replaced by acetic acid at pH 2 with two washes. In this way, magnetic nanoparticles with their partially modified surface with carboxyl groups are obtained.
- Chondroitin sulfate salts are dissolved in a 10 mM solution of 4- (2-hydroxyethyl) -1-piperazinotanosulfonic acid) HEPES.
- the magnetite nanoparticles with their partially functionalized surface obtained above are added, with an iron concentration of approximately 1 molar with respect to chondroitin sulfate monomers, together with N- (3- dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (EDC) in an excess of 1, 21: 1 also with respect to chondroitin sulfate monomers.
- EDC N- (3- dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride
- the resulting suspension is stabilized at pH 7.4, left under stirring at 4 ° C for 24 h and the excess is removed by filtration or dialysis.
- the nanoparticles functionalized with chondroitin sulfate are added to aqueous mixtures of additional chondroitin sulfate, other glycosoaminglicans or glycoproteins used in cartilage implants.
- the mixture is stirred to form a gel.
- Said gel can be included in cartilage implants and chondroitin sulfate or sulfatase hydrolases, which play a role in cartilage regeneration, act as a reporter of the activity.
- EXAMPLE 4 MANUFACTURE OF A GEL UNDERSTANDING A COLLAGEN WITH MAGNETIC FUNCTIONALITY
- a solution of 1.5 mg / ml of Type I collagen in 0.1% acetic acid is stabilized at pH 7.4 with 0.4 M NaOH in 10X D- PBS and 250mM HEPES, ribose is added until reaching 250 mM, a collagen suspension with magnetic functionality at a concentration of 1.5 mg / ml, hyaluronic acid at a final concentration of less than 1%, the mixture is again stabilized at pH 7.4 and allowed to incubate for 72 h at 4 ° C. Subsequently, washings are performed and sonication at 4 ° C with a solution of NaOH at pH 8. Finally, the gel is incubated at 37 ° C for 45 minutes.
- the resulting gel is semi-solid can be used for in vitro assays or, form an implant that once implanted, capable of replacing connective tissue.
- the inclusion of hyaluronic acid favors its invasion by fibroblasts which secrete collagenases and in turn degrading the implant's own collagen and replacing it with collagen with a morphology similar to that of the surrounding tissue.
- the previous degradation of collagens causes the aggregation of the magnetic particles which can be detected by means of weighted magnetic resonance imaging maps.
- EXAMPLE 5 MANUFACTURE OF AN IMPLANT UNDERSTANDING A HIALURONIC ACID WITH MAGNETIC FUNCTIONALITY
- the collagen with magnetic functionality is replaced by a 2% solution of hyaluronic acid with magnetic functionality stabilized at pH 7.4.
- the implant obtained allows the degradation of said implant to be detected by the activity of the hiluronidase. It is also possible to concentrically combine several types of implants by gelling a new incubation at 4 ° C on an implant already prepared, but with a compound with different functionality. In this way, it is possible to detect more than one enzyme activity in the same implant depending on which region of the same occurs.
- EXAMPLE 5 MANUFACTURE OF AN INJECTABLE IMPLANT UNDERSTANDING A HIALURONIC ACID WITH MAGNETIC FUNCTIONALITY
- a suspension of 4 mg / ml of Type I collagen with magnetic functionality in 0.1% acetic acid is mixed with a solution of hyaluronic acid at a concentration of 3% also in 0.1% acetic acid.
- the mixture is stabilized at pH 7.4 with 0.4 M NaOH in 10X D-PBS and 250mM HEPES at 4 ° C and is brought to a final concentration of 1 mg / ml of Type I collagen with magnetic functionality and 1% hyaluronic acid at pH 7.4.
- the resulting gel once implanted, is able to give elasticity and replace connective tissue once injected.
- the presence of hyaluronic acid favors its invasion by fibroblasts which secrete collagenases and in turn degrading the implant's own collagen and replacing it with its own collagen.
- the previous degradation of the collagen causes the aggregation of the magnetic particles which can be detected by means of weighted magnetic resonance image maps.
- EXAMPLE 6 PREPARATION OF A COMPOUND WITH MAGNETIC FUNCTIONALITY THROUGH CHANGES WITH MAGNETIC NANOPARTICLES OPERATED WITH CARBOXYL GROUPS
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Materials For Medical Uses (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/409,584 US20150174272A1 (en) | 2012-06-21 | 2013-06-21 | Compounds having magnetic functionality, implants or gels derived from same, and use of both in order to determine the enzyme activity of an enzyme |
CN201380042510.9A CN104540529A (zh) | 2012-06-21 | 2013-06-21 | 具有磁功能性的化合物、得自其的植入物或凝胶以及二者用于测量酶的酶活性的用途 |
AU2013279221A AU2013279221A1 (en) | 2012-06-21 | 2013-06-21 | Compounds having magnetic functionality, implants or gels derived from same, and use of both in order to determine the enzyme activity of an enzyme |
CA 2877058 CA2877058A1 (en) | 2012-06-21 | 2013-06-21 | Compounds with magnetic functionality, implants or gels derived thereof, and the use of both to measure the enzyme activity of an enzyme |
JP2015517814A JP2015522568A (ja) | 2012-06-21 | 2013-06-21 | 磁気機能性を有する化合物、それから派生したインプラント又はゲル、及び酵素の酵素活性を測定するための両方の使用 |
EP13806520.6A EP2865394A4 (en) | 2012-06-21 | 2013-06-21 | MAGNETICALLY FUNCTIONALITY COMPOUNDS, IMPLANTS OR GELS DERIVED THEREFROM, AND USE THEREOF FOR DETERMINING THE ENZYMATIC ACTIVITY OF AN ENZYME |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201230972A ES2439167B1 (es) | 2012-06-21 | 2012-06-21 | Compuestos con funcionalidad magnética, implantes o geles derivados de ellos, y el uso de ambos para determinar la actividad enzimática de una enzima |
ESP201230972 | 2012-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013190165A1 true WO2013190165A1 (es) | 2013-12-27 |
Family
ID=49768169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2013/070407 WO2013190165A1 (es) | 2012-06-21 | 2013-06-21 | Compuestos con funcionalidad magnética, implantes o geles derivados de ellos, y el uso de ambos para determinar la actividad enzimática de una enzima |
Country Status (8)
Country | Link |
---|---|
US (1) | US20150174272A1 (es) |
EP (1) | EP2865394A4 (es) |
JP (1) | JP2015522568A (es) |
CN (1) | CN104540529A (es) |
AU (1) | AU2013279221A1 (es) |
CA (1) | CA2877058A1 (es) |
ES (1) | ES2439167B1 (es) |
WO (1) | WO2013190165A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3222711A4 (en) * | 2014-11-21 | 2018-07-11 | Universidad de Granada | Production of artificial tissues comprising magnetic particles |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9835569B2 (en) | 2013-09-25 | 2017-12-05 | Toyota Jidosha Kabushiki Kaisha | Magnetic measurement system and apparatus utilizing X-ray to measure comparatively thick magnetic materials |
JP6411722B2 (ja) * | 2013-09-25 | 2018-10-24 | トヨタ自動車株式会社 | 磁気特性測定方法 |
EP3154552B1 (en) * | 2014-06-11 | 2021-03-24 | International Scientific Pty Ltd | Device and method to treat or prevent joint degeneration |
BR112020011294A2 (pt) * | 2017-12-04 | 2020-11-17 | Evonik Operations Gmbh | corpo com várias fases e o emprego do mesmo |
CN109517781B (zh) * | 2018-11-23 | 2022-07-08 | 四川大学 | 具有可洗脱超顺磁凝胶涂层的细胞-微球及其制备方法与应用 |
CN110246641B (zh) * | 2019-05-05 | 2021-08-27 | 桂林理工大学 | 一种制备良好分散性的降解透明质酸修饰的超顺磁性氧化铁纳米粒子的方法 |
EP3805402A1 (en) * | 2019-10-10 | 2021-04-14 | ETH Zurich | Non-invasive method for detection of enzyme activity in vivo, substrates and a device therefore |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030170173A1 (en) * | 2000-05-23 | 2003-09-11 | Jo Klaveness | Contrast agents |
US20070166810A1 (en) * | 2005-12-23 | 2007-07-19 | Perkinelmer Las, Inc. | Methods and compositions for detecting enzymatic activity |
WO2011075476A1 (en) | 2009-12-14 | 2011-06-23 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Methods and compositions relating to reporter gels for use in mri techniques |
US20110182815A1 (en) | 2010-01-22 | 2011-07-28 | Julian Daich | Method for the detection of enzymatic activity with magnetically functionalized substrates |
US20120107229A1 (en) * | 2009-04-15 | 2012-05-03 | Xuefei Huang | Novel nano-probes for molecular imaging and targeted therapy of diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999055230A1 (en) * | 1998-04-28 | 1999-11-04 | Jagotec Ag | Hyaluronan-based imaging agents |
AU4161399A (en) * | 1998-05-26 | 1999-12-13 | Bar-Ilan University | Nucleation and growth of magnetic metal oxide nanoparticles and its use |
CA2492803C (en) * | 2002-07-19 | 2013-11-05 | The General Hospital Corporation | Oxime conjugates and methods for their formation and use |
GB0510461D0 (en) * | 2005-05-23 | 2005-06-29 | Namosphere Ltd | Assay particles |
-
2012
- 2012-06-21 ES ES201230972A patent/ES2439167B1/es not_active Expired - Fee Related
-
2013
- 2013-06-21 WO PCT/ES2013/070407 patent/WO2013190165A1/es active Application Filing
- 2013-06-21 JP JP2015517814A patent/JP2015522568A/ja active Pending
- 2013-06-21 US US14/409,584 patent/US20150174272A1/en not_active Abandoned
- 2013-06-21 AU AU2013279221A patent/AU2013279221A1/en not_active Abandoned
- 2013-06-21 CN CN201380042510.9A patent/CN104540529A/zh active Pending
- 2013-06-21 EP EP13806520.6A patent/EP2865394A4/en not_active Withdrawn
- 2013-06-21 CA CA 2877058 patent/CA2877058A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030170173A1 (en) * | 2000-05-23 | 2003-09-11 | Jo Klaveness | Contrast agents |
US20070166810A1 (en) * | 2005-12-23 | 2007-07-19 | Perkinelmer Las, Inc. | Methods and compositions for detecting enzymatic activity |
US20120107229A1 (en) * | 2009-04-15 | 2012-05-03 | Xuefei Huang | Novel nano-probes for molecular imaging and targeted therapy of diseases |
WO2011075476A1 (en) | 2009-12-14 | 2011-06-23 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Methods and compositions relating to reporter gels for use in mri techniques |
US20110182815A1 (en) | 2010-01-22 | 2011-07-28 | Julian Daich | Method for the detection of enzymatic activity with magnetically functionalized substrates |
Non-Patent Citations (10)
Title |
---|
A. ROCH; F. MONKY; R.N. MULLER; P. GILLIS, WATER MAGNETIC RELAXATION IN SUPERPARAMAGNETIC COLLOID SUSPENSIONS: THE EFFECT OF AGGLOMERATION |
J MAGN RESON IMAGING, vol. 26, no. 6, December 2007 (2007-12-01), pages 1634 - 41 |
J. FRAISSARD; O. LAPINA, MAGNETIC RESONANCE IN COLLOIDS AN INTERFACE SCIENCE, pages 383 - 92 |
JOHN M. WALKER: "Methods in molecular biology", vol. 480, SPRINGER PROTOCOLS, article "Macromolecular drug delivery: methods and protocols" |
LACONTE LE; NITIN N; ZURKIYA 0; CARUNTU D; O'CONNOR CJ; HU X; BAO G., COATING THICKNESS OF MAGNETIC IRON OXIDE NANOPARTICLES AFFECTS R2 RELAXIVITY |
MIN-JUNG KIM; DAE-HWAN JANG; YONG-HO CHOAE, PHYSICA SCRIPTA T, vol. 139, 2010, pages 14024 |
MITCHELL ET AL.: "MRI Principles", 1999 |
See also references of EP2865394A4 |
SOMERS KD; DAWSON DM: "Fibrin deposition in Peyronie's disease plaque", J. UROL., vol. 157, no. 1, January 1997 (1997-01-01), pages 311 - 5, XP005571727, DOI: doi:10.1016/S0022-5347(01)65367-9 |
WOESSNER JF JR.: "Matrix metalloproteinases and their inhibitors in connective tissue remodelling", FASEB J., vol. 5, no. 8, May 1991 (1991-05-01), pages 2145 - 54 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3222711A4 (en) * | 2014-11-21 | 2018-07-11 | Universidad de Granada | Production of artificial tissues comprising magnetic particles |
Also Published As
Publication number | Publication date |
---|---|
EP2865394A4 (en) | 2016-01-27 |
EP2865394A1 (en) | 2015-04-29 |
CA2877058A1 (en) | 2013-12-27 |
AU2013279221A1 (en) | 2015-01-22 |
US20150174272A1 (en) | 2015-06-25 |
JP2015522568A (ja) | 2015-08-06 |
CN104540529A (zh) | 2015-04-22 |
ES2439167A1 (es) | 2014-01-21 |
ES2439167B1 (es) | 2014-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013190165A1 (es) | Compuestos con funcionalidad magnética, implantes o geles derivados de ellos, y el uso de ambos para determinar la actividad enzimática de una enzima | |
Zhou et al. | Multifunctional luminescent immuno-magnetic nanoparticles: toward fast, efficient, cell-friendly capture and recovery of circulating tumor cells | |
Ai | Layer-by-layer capsules for magnetic resonance imaging and drug delivery | |
Kim et al. | Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T 1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells | |
Tu et al. | Activatable T 1 and T 2 magnetic resonance imaging contrast agents | |
Samal et al. | Biomimetic magnetic silk scaffolds | |
Rodriguez-Arco et al. | Biocompatible magnetic core–shell nanocomposites for engineered magnetic tissues | |
Chen et al. | Remote control of mechanical forces via mitochondrial‐targeted magnetic nanospinners for efficient cancer treatment | |
Wang et al. | Antifouling manganese oxide nanoparticles: synthesis, characterization, and applications for enhanced MR imaging of tumors | |
KR20160091993A (ko) | 바이오패브리케이션 및 프린팅을 위한 빌딩 블록으로서의 자기 조립형 펩티드, 펩티드 모방체 및 펩티드 접합체 | |
Huang et al. | Redox-sensitive polymer/SPIO nanocomplexes for efficient magnetofection and MR imaging of human cancer cells | |
Chen et al. | Guidance of stem cells to a target destination in vivo by magnetic nanoparticles in a magnetic field | |
Naghdi et al. | Magnetic nanocomposites for biomedical applications | |
Zhang et al. | Injectable and pH-responsive self-assembled peptide hydrogel for promoted tumor cell uptake and enhanced cancer chemotherapy | |
Jaganathan et al. | Examining MRI contrast in three-dimensional cell culture phantoms with DNA-templated nanoparticle chains | |
US9999691B2 (en) | Method for the detection of enzymatic activity with magnetically functionalized substrates | |
Xiaoming et al. | Safe and potent MRI contrast agents by complexing gadolinium with enzyme/reduction dual-sensitive branched polymers | |
Geng et al. | Supramolecular design based activatable magnetic resonance imaging | |
López-Cebral et al. | Progress in the characterization of bio-functionalized nanoparticles using NMR methods and their applications as MRI contrast agents | |
Mukherjee et al. | Site-specific amphiphilic magnetic copolymer nanoaggregates for dual imaging | |
Smith et al. | Worm-like superparamagnetic nanoparticle clusters for enhanced adhesion and magnetic resonance relaxivity | |
Zhang et al. | Polarization of stem cells directed by magnetic field-manipulated supramolecular polymeric nanofibers | |
Linot et al. | PEGylated anionic magnetofluorescent nanoassemblies: impact of their interface structure on magnetic resonance imaging contrast and cellular uptake | |
Lv et al. | Nanomaterials-Mediated Therapeutics and Diagnosis Strategies for Myocardial Infarction | |
Xuan et al. | Ultrasound molecular imaging with cRGD-PLGA-PFOB nanoparticles for liver fibrosis staging in a rat model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13806520 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2877058 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015517814 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14409584 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013806520 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013279221 Country of ref document: AU Date of ref document: 20130621 Kind code of ref document: A |